预测肾动脉支架置入术后肾功能反应
基于退伍军人事务企业数据仓库2000至2021年695例肾动脉支架置入患者,中位随访7.1年,202例(29.1%)为肾功能应答者。逻辑回归识别糖尿病(OR 0.64)、CKD 3b或4期(OR 1.80)及术前eGFR每周下降速率(OR 1.21)为预测因素。
要点
- CKD 3b或4期患者是唯一有显著肾功能改善概率的亚组。
- 术前eGFR下降越快,支架术后肾功能改善概率越大。
- 糖尿病是肾功能改善的负性预测因素,对糖尿病患者行肾动脉支架置入应谨慎。
核心结论
- CKD 3b和4期(eGFR 15-44 mL/min/1.73 m2)是唯一有显著肾功能改善概率的亚组。
- 术前eGFR下降速率是预测肾动脉支架置入获益的有力判别指标,下降越快改善概率越大。
- 糖尿病是肾功能改善的负性预测因素,介入医生对糖尿病患者行肾动脉支架置入应谨慎。
研究设计与样本
- 回顾性队列研究,查询退伍军人事务企业数据仓库2000至2021年接受肾动脉支架置入的患者。
- 共纳入695例患者,中位随访7.1年(四分位距3.7-11.6年)。
- 主要结局为支架术后eGFR改善,术后30天或更晚eGFR较术前增加20%或以上定义为应答者。
主要发现
- 202例(29.1%)为应答者,493例(70.9%)为非应答者。
- 应答者支架术后eGFR较术前增加26.1%(P < .0001),随访期间保持稳定;非应答者支架术后eGFR进行性下降5.5%。
- 术前应答者平均血清肌酐显著更高、平均eGFR更低、术前数月eGFR下降速率更高。
- 逻辑回归识别三个预测因素:糖尿病(OR 0.64;95%CI 0.44-0.91;P = .013)、CKD 3b或4期(OR 1.80;95%CI 1.26-2.57;P = .001)、术前eGFR每周下降速率(OR 1.21;95%CI 1.05-1.39;P = .008)。
关键数值与推荐
- 应答者定义:支架术后30天或更晚eGFR较术前增加20%或以上。
- CKD 3b和4期对应eGFR 15-44 mL/min/1.73 m2。
- 糖尿病OR 0.64(95%CI 0.44-0.91;P = .013)。
- CKD 3b或4期OR 1.80(95%CI 1.26-2.57;P = .001)。
- 术前eGFR每周下降速率OR 1.21(95%CI 1.05-1.39;P = .008)。
临床怎么用
- 作者认为CKD 3b和4期(eGFR 15-44 mL/min/1.73 m2)患者是肾动脉支架置入后肾功能有显著改善概率的唯一亚组。
- 作者认为术前eGFR下降速率是判别最可能从肾动脉支架置入获益患者的有力指标,术前eGFR下降越快改善概率越大。
- 作者认为糖尿病是肾功能改善的负性预测因素,介入医生对糖尿病患者行肾动脉支架置入应谨慎。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Cardiovascular Outcomes in Renal Atherosclerotic Lesions Trial found no benefit of renal artery stenting (RAS) over medical therapy, although it was underpowered to detect a benefit among patients with chronic kidney disease (CKD). A post hoc analysis demonstrated improved event-free survival after RAS for patients whose renal function improved by 20% or more. A significant obstacle to achieving this benefit is the inability to predict which patients' renal function will improve from RAS. The objectives of the current study were to identify predictors of renal function response to RAS. METHODS: The Veteran Affairs Corporate Data Warehouse was queried for patients who underwent RAS between 2000 and 2021. The primary outcome was improvement in renal function (estimated glomerular filtration rate [eGFR]) after stenting. Patients were categorized as responders if the eGFR at 30 days or greater after stenting increased by 20% or more compared with before stenting. All others were nonresponders. RESULTS: The study cohort included 695 patients with a median follow-up of 7.1 years (interquartile range, 3.7-11.6 years). Based on postoperative change in eGFR, 202 stented patients (29.1%) were responders, and the remainder (n = 493 [70.9%]) were nonresponders. Before RAS, responders had a significantly higher mean serum creatinine, lower mean eGFR, and higher rate of decline of preoperative GFR in the months before stenting. After stenting, responders had a 26.1% increase in eGFR, compared with before stenting (P < .0001), which remained stable during follow-up. In contrast, nonresponders had a progressive 5.5% decrease in eGFR after stenting. Logistic regression analysis identified three predictors of renal function response to stenting: (1) diabetes (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.44-0.91; P = .013), (2) CKD stages 3b or 4 (OR, 1.80; 95% CI, 1.26-2.57; P = .001), and (3) rate of decline in preoperative eGFR per week before stenting (OR, 1.21; 95% CI, 1.05-1.39; P = .008). CKD stages 3b and 4 and the rate of decline in preoperative eGFR are positive predictors of renal function response to stenting, whereas diabetes is a negative predictor. CONCLUSIONS: Based on our data, patients in CKD stages 3b and 4 (eGFR 15-44 mL/min/1.73 m2) are the only subgroups with a significant probability of improved renal function after RAS. The rate of decline of preoperative eGFR over the months before stenting is a powerful discriminator of patients who are most likely to benefit from RAS. Specifically, patients with a more rapid decrease in eGFR before stenting have a significantly greater probability of improved renal function with RAS. In contrast, diabetes is a negative predictor of improved renal function, so interventionalists should be circumspect about RAS in diabetic patients.
引用
- Modrall JG, Jeon-Slaughter H, Ramanan B, et al. Predicting renal function response to renal artery stenting. J Vasc Surg. 2023. PMID: 36868330. doi:10.1016/j.jvs.2023.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。